By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


IFM Therapeutics 

400 Technology Square, 10th Floor

Cambridge  Massachusetts  02139  U.S.A.
Phone: n/a Fax: n/a


IFM Therapeutics is a privately held biopharmaceutical company based in Cambridge, Massachusetts. Seeded by Atlas Venture, the company was founded in 2015 by an international group of preeminent scientists and physicians to discover and develop small molecules that modulate novel targets in the innate immune system as next generation therapies for cancer, autoimmunity, and inflammatory disorders. Drugs in the IFM portfolio are expected to significantly improve upon standard of care agents in terms of efficacy and safety. For more information, please visit


October 2011


CEO: Gary D. Glick

Chief Development Officer: Dennis Dean

Chief Scientific Officer: Shomir Ghosh

Key Statistics

Ownership: Private

Web Site: IFM Therapeutics


Company News
Regen BioPharma Addresses Potential Impact of Recent Bristol-Myers Squibb (BMY)'s $2.3 Billion Acquisition Of IFM Therapeutics 8/10/2017 1:48:35 PM
Regen BioPharma Addresses Potential Impact Of Recent Bristol-Myers Squibb (BMY) $2.3 Billion Acquisition Of IFM Therapeutics 8/9/2017 11:57:00 AM
IFM Therapeutics Appoints H. Martin Seidel As Executive Vice President Of Research And Development 5/23/2017 8:09:24 AM
IFM Therapeutics Appoints Renowned Physicians From Academia And Industry To Clinical Advisory Board 2/23/2017 6:40:15 AM
IFM Therapeutics Establishes German Subsidiary And Research Site 10/26/2016 10:43:14 AM
IFM Therapeutics Appoints Leading Oncology, Immunology, And Chemistry Experts To Founding Scientific Advisory Board 9/6/2016 11:35:10 AM
Cambridge Upstart IFM Therapeutics Banks $27 Million from Investors Like Novartis AG (NVS) and Atlas Venture 6/22/2016 6:27:32 AM